{"version":"1.0","provider_name":"EVER Pharma","provider_url":"https:\/\/www.everpharma.com\/de\/","author_name":"Magdalena","author_url":"https:\/\/www.everpharma.com\/de\/author\/mschmitzberger\/","title":"EVER Pharma erh\u00e4lt EU-Zulassung f\u00fcr Trabectedin - EVER Pharma","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"xsGA9CdiLp\"><a href=\"https:\/\/www.everpharma.com\/de\/news\/ever-pharma-erhaelt-eu-zulassung-fuer-trabectedin\/\">EVER Pharma erh\u00e4lt EU-Zulassung f\u00fcr Trabectedin<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.everpharma.com\/de\/news\/ever-pharma-erhaelt-eu-zulassung-fuer-trabectedin\/embed\/#?secret=xsGA9CdiLp\" width=\"600\" height=\"338\" title=\"&#8222;EVER Pharma erh\u00e4lt EU-Zulassung f\u00fcr Trabectedin&#8220; &#8211; EVER Pharma\" data-secret=\"xsGA9CdiLp\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.everpharma.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"EVER Pharma freut sich, die EU-weite Zulassung von Trabectedin (0,25MG und 1MG) f\u00fcr die Behandlung von fortgeschrittenen Weichteilsarkomen und Eierstockkrebs1 bekannt zu geben. Weichteilsarkome und Eierstockkrebs sind seltene Krebsarten, von denen in der Europ\u00e4ischen Union insgesamt etwa 150 000 Patient*innen&nbsp;betroffen sind. Trabectedin wird f\u00fcr die Behandlung des fortgeschrittenen Weichteilsarkoms&nbsp;empfohlen2. Es ist auch eine wichtige Behandlungsoption &hellip; Weiterlesen","thumbnail_url":"https:\/\/www.everpharma.com\/wp-content\/uploads\/2023\/06\/Trabectedin_Combination-Pack-Shots-1024x1024.png"}